Vyondys 53

Chemical Namegolodirsen
Dosage FormInjection (intravenous; 50 mg/mL)
Drug ClassOligonucleotides
SystemMusculoskeletal
CompanySarepta Therapeutics
Approval Year2019

Indication

  • For the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping
Last updated on 4/8/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vyondys 53 (golodirsen) Prescribing Information.2019Sarepta Therapeutics, Inc. Cambridge, MA